David Bauer

Simpson Thacher & Bartlett advised CSG Systems International, Inc., and Davis Polk & Wardwell advised the representatives of the initial purchasers on the offering. CSG Systems...

Davis Polk & Wardwell represented the initial purchasers in the offering. Tetra Tech, Inc. announced its Rule 144A offering of $575 million aggregate principal amount of its 2.25%...

Cooley advised AN2 Therapeutics, Inc., and Davis Polk & Wardwell advised the joint book-running managers on the offering. AN2 Therapeutics, Inc. (Nasdaq:ANTX) announced a SEC-registered follow-on...

Cooley LLP advised NGM Biopharmaceuticals, while Davis Polk & Wardwell advised Jefferies, as sales agent in the offering. NGM Biopharmaceuticals (NASDAQ:NGM) announced its common stock for up to...

Davis Polk & Wardwell advised Immedica Pharma AB on the transaction. Immedica Pharma AB announced its acquisition from Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) of all assets related...

Davis Polk & Wardwell advised Immatics N.V. in the deal. Immatics N.V. announced its $35 million private placement of ordinary shares. All of the shares were purchased...

Goodwin Procter is serving as legal counsel to Korro Bio, Latham & Watkins is serving as Frequency Therapeutics’ legal counsel, and Davis Polk is serving as...

Davis Polk & Wardwell is advising Centogene N.V., while Latham & Watkins is advising Lifera in the transaction. Centogene N.V., a life science company focused on...

Davis Polk advised the joint book-running managers in the offering. Editas Medicine, Inc. (Nasdaq: EDIT) announced the pricing of an underwritten offering of 12,500,000 shares of its...

Davis Polk advised BofA Securities, Inc., SVB Securities LLC on the offering. Cooley LLP represented Oculis Holding in the offering. Vischer AG advised Oculis Holding for...

Davis Polk advised Morgan Stanley & Co. LLC and Wedbush Securities Inc. on the offering. TScan Therapeutics, a biopharmaceutical company, has announced a $140.6 million SEC-registered common...

Davis Polk advised the sales agents, RBC Capital Markets, LLC and Evercore Group L.L.C., on the transaction. Emergent BioSolutions Inc., an American multinational specialty biopharmaceutical company headquartered in...